Product nameAnti-VEGFA antibody
See all VEGFA primary antibodies
DescriptionRabbit polyclonal to VEGFA
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
- IHC-P: Human liver cancer tissue. WB: Hela, Jurkat, HEK-293T, HT29, MDA-MB-231, A549, SK-OV-3 and 231 cell lysates.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.30
Preservative: 0.05% Sodium azide
Constituents: 50% Glycerol, 49% PBS
without Mg2+ and Ca2+)
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab183100 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/450 - 1/2000. Predicted molecular weight: 27 kDa.|
|IHC-P||1/25 - 1/100.|
FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
- Information by UniProt
- Folliculostellate cell-derived growth factor antibody
- Glioma-derived endothelial cell mitogen antibody
- MGC70609 antibody
Immunohistochemical analysis of paraffin embedded Human liver cancer tissue labeling VEGFA with ab183100 at 1/25. Image on the right is treated with the synthetic peptide.
All lanes : Anti-VEGFA antibody (ab183100) at 1/450 dilution
Lane 1 : Hela cell lysate
Lane 2 : Jurkat cell lysate
Lane 3 : 293T cell lysate
Lane 4 : 231 cell lysate
Lysates/proteins at 40 µg per lane.
All lanes : Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution
Predicted band size: 27 kDa
Exposure time: 2 minutes
All lanes : Anti-VEGFA antibody (ab183100) at 1/1000 dilution
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) cell lysate
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) cell lysate
Lane 3 : HepG2 (human liver hepatocellular carcinoma cell line) cell lysate
Lane 4 : HT29 cell lysate
Lane 5 : MDA-MB-231 (human breast adenocarcinoma cell line) cell lysate
Lane 6 : A549 (human lung carcinoma cell line) cell lysate
Lane 7 : SK-OV-3 (human ovarian cancer cell line) cell lysate
Lysates/proteins at 30 µg per lane.
All lanes : Goat anti Rabbit IgG - H&L (HRP) at 1/100 dilution
Developed using the ECL technique.
Predicted band size: 27 kDa
This product has been referenced in:
- Wei X et al. GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma. BMC Cancer 18:600 (2018). Read more (PubMed: 29843634) »
- Zheng J et al. Evaluation of metastatic niches in distant organs after surgical removal of tumor-bearing lymph nodes. BMC Cancer 18:608 (2018). Read more (PubMed: 29848296) »